Moderna’s chief executive officer doesn’t expect any problems with the development of a booster shot against the latest strain of the CCP virus and hopes clinical trials can begin early next year. “It only needs minor adjustments for Omicron. I don’t expect any problems,” Stéphane Bancel told Swiss newspaper Tages-Anzeiger, likely referring to the company’s currently authorized 50 microgram dose booster of its mRNA-1273 vaccine. Bancel noted that the biotechnology company is currently only awaiting important information on Omicron to begin development. “That will take another week or two,” Bancel said, adding that “it will take a few months before we can produce 500 million doses after approval.” If the U.S. Food and Drug Administration (FDA), Switzerland’s Swissmedic, and other regulatory agencies require further studies, then that would add at least three months, he said. “Some authorities want a study, others are still undecided,” Bancel told the paper. “In my opinion, it …